Predicted cardiovascular disease risk following chemotherapy and radiotherapy for early-stage Hodgkin lymphoma

Analysis of the UK RAPID trial investigated individualized risk of radiation-related cardiovascular disease in patients receiving ABVD chemotherapy and involved field radiotherapy for early-stage Hodgkin lymphoma (ES-HL). The analysis found that predicted excess cardiovascular risk was small for most patients, so RT might provide net benefit. However, for a minority of patients receiving high doses of radiation to cardiovascular structures, it may be preferable to consider advanced RT techniques to reduce doses or to omit RT and accept the increased relapse risk.